← Back to Search

Virus Therapy

COVID Convalescent Plasma for COVID-19

Phase < 1
Waitlist Available
Led By Gailen D Marshall, Jr., MD, PhD
Research Sponsored by Gailen D. Marshall Jr., MD PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1, 3, 7, and 28
Awards & highlights

Study Summary

This trial is testing if convalescent plasma can help people with severe or life-threatening COVID-19.

Eligible Conditions
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1, 3, 7, and 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 1, 3, 7, and 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in PaO2/FiO2 after CCP transfusion.
Change in aO2 after CCP transfusion.
Change in intubation status after CCP transfusion.
+2 more
Secondary outcome measures
Change in 8-point ordinal clinical deterioration scale.
Change in Sequential Organ Failure Assessment (SOFA).
Change in anti CoV-2 IgM and IgG levels.
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Recipient of COVID-19 Convalescent Plasma (CCP) TransfusionExperimental Treatment1 Intervention
Transfusion of COVID-19 convalescent plasma to participants with serious or life threatening complications from COVID-19 or are at high risk to develop serious complications.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
COVID Convalescent Plasma
2020
Completed Early Phase 1
~230

Find a Location

Who is running the clinical trial?

Gailen D. Marshall Jr., MD PhDLead Sponsor
University of Mississippi Medical CenterOTHER
173 Previous Clinical Trials
195,001 Total Patients Enrolled
1 Trials studying COVID-19
120 Patients Enrolled for COVID-19
Gailen D Marshall, Jr., MD, PhDPrincipal InvestigatorUniversity of Mississippi Medical Center
4 Previous Clinical Trials
550 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
COVID-19 Convalescent Plasma (CCP) Transfusion
Gailen D. Marshall Jr., MD PhD 2020. "COVID-19 Convalescent Plasma (CCP) Transfusion". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04412486.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top